Pharmacoeconomics

Article	Citations
Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”	131
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling	117
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?	72
Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment	67
Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment	61
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting	57
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children	54
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment	51
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment	44
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis	39
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy	39
The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned	37
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy	37
Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review	36
Advancing Methods to Measure and Reward Healthcare Innovation	36
Bayesian Meta-Analysis: A Practical Introduction	35
Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review	34
Innovation Headroom for a Highly Accurate PD-L1 Companion Diagnostic in Non-small Cell Lung Cancer	34
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States	31
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based	31
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation	31
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling	31
The Economic Burden of Inflammatory Arthritis: A Systematic Review	30
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review	29
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies	29

Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA	28
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions	28
Caring for and Caring about in Economic Evaluation: Modelling the Family and Caregiving Effects	27
A Framework for Reliable, Transparent, and Reproducible Population-Adjusted Indirect Comparisons	26
Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective	25
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition	25
The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations	24
Time to Close the Gap Between Guidelines and the Reimbursement Policy for Diabetes Treatment in Turkey	24
An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada	24
A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes	24
Market Transparency in Medicine Pricing: Pathways to Fair Pricing	23
Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review	23
The Use of Real-World Data for Estimating Relative Treatment Effects in NICE Health Technology Assessment Submissions: A Review	23
Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know	22
Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD)	22
Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review	22
A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries	22
Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap	22
Measuring the Direct Medical Costs of Hospital-Onset Infections Using an Analogy Costing Framework	21
Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program	20
Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models	20
Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs	20
Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual Considerations	19
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia	19
A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)	19
Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators	18
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry	18
Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds	18
Economic and Humanistic Burden of Osteoarthritis: An Updated Systematic Review of Large Sample Studies	18
Prognostic Testing for Prostate Cancer—A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice	17
A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates	16
Acknowledgement to Referees	16
Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia	16
Comparison of EQ-5D-Y-3L Utility Scores Using Nine Country-Specific Value Sets in Chinese Adolescents	16
Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis	15
Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated	15
Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria	15
Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Mye	15
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China	14
Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures	14
A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models	14
Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer	13
Measuring the Indirect Cost of Illness Using EQ-5D-5L While Accounting for Job Characteristics	13
Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC)	13
Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis	13
Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection	13
Modelling the Cost-Effectiveness of Diagnostic Tests	13
Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review	12
A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework	12
The Costs of Dementia in Europe: An Updated Review and Meta-analysis	12

Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability	12
Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”	12
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA	12
Economic Implications of Endometriosis: A Review	12
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments	12
Uncertainty in Matching-Adjusted Indirect Comparisons Using Real-World Evidence: Evidence Assessment Group Perspective	12
The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer’s Disease in Sweden	12
Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom	12
Health Care Resource Utilization and Costs Associated with US Medicaid Sobriety Restrictions on Direct-Acting Antivirals for Hepatitis C Virus: A Retrospective Claims Database Analysis	12
How do Health State Values Differ When Respondents Consider Adults Versus Children Living in Those States? A Systematic Review	11
Economic Evaluation of Interventions to Reduce Antimicrobial Resistance: A Systematic Literature Review of Methods	11
Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision	11
Childhood Transitions Between Weight Status Categories: Evidence from the UK Millennium Cohort Study	11
Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?	11
Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations	11
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments	11
Societal Versus Healthcare Perspectives on the Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis in Aotearoa New Zealand	11
Systematic Review of the Relative Social Value of Child and Adult Health	11
Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review	11
Considerations Around the Inclusion of Children and Young People’s Time in Economic Evaluation: Findings from an International Delphi Study	11
A Value Set for the EQ-5D-Y-3L in the Netherlands	10
Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review	10
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan	10
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer	10
Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation	10
Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias	10
Informal Caregiving Provision for Disabled or Elderly in the Families and Work Productivity: Evidence from 11 Waves of an Australian Population-Based Cohort	10
Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer	10
Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges	10
Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time	9
Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments	9
Using AI in the Economic Evaluation of AI-Based Health Technologies	9
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study	9
HTA Barriers for Conditional Approval Drugs	9
Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses	9
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK	9
Incorporating Complexity and System Dynamics into Economic Modelling for Mental Health Policy and Planning	9
Correction: Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis	9
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meni	9
Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L	9
A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process	9
Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Colistin + Meropenem (COL + MER) for the Treatment of Infections Caused by Metallo-β-Lactamase (MBL)-Producing Enterobacterales in I	8
Economic Impact of Insufficient and Disturbed Sleep in the Workplace	8
How Much Better is Faster? Empirical Tests of QALY Assumptions in Health-Outcome Sequences	8
PharmacoEconomics Supplement	8
Does the Informal Carer Identification Method Matter? Evidence from Self-Declaration and Time Diary Approaches	8
PharmacoEconomics	8
A Prototype Software Framework for Transferable Computational Health Economic Models and Its Early Application in Youth Mental Health	8
Measuring Effectiveness Based on Patient Experience (Instead of QALYs) in US Value Assessments	8
Acceptance of Evidence Transfer Within German Early Benefit Assessment of New Drugs for Pediatric and Adolescents Target Populations	8
Developing a Framework of Cost Elements of Socioeconomic Burden of Rare Disease: A Scoping Review	8
Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Liv	8
Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzer	8
MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial	8
China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population	7
Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	7
Exploring the Generalizability of Foreign Cost-Effectiveness Analysis to Spain Using Data From a Scoping Review of Multinational Studies	7
Patient and Public Involvement in Health Economics Modelling Raises the Need for Normative Guidance	7
A Framework for the Fair Pricing of Medicines	7
Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US	7
Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care Costs	7
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US	7
Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States	7
Efficiency of the EmERGE Pathway of Care in Five European HIV Centres	7
Cost-of-Illness of Skin Cancer: A Systematic Review	7
Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service	7
Inequalities in Quality-Adjusted Life Expectancy in Australia by Educational Attainment	7
Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression	7
Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on Cost-Effectiveness Analyses	7
NICE Approaches to Expert Opinion Evidence in Highly Specialised Technologies: Time to Change? Evidence Assessment Group Perspective	6
Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review	6
Cost-Effectiveness of Emerging Treatments for Atopic Dermatitis: A Systematic Review	6
Cost-Utility Analysis of Universal Maternal Pertussis Immunisation in Thailand: A Comparison of Two Model Structures	6
Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States	6
A Comparison of the Content and Consistency of Methodological Quality and Transferability Checklists for Reviewing Model-Based Economic Evaluations	6
Engaging Patients and Caregivers in an Early Health Economic Evaluation: Discerning Treatment Value Based on Lived Experience	6
In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era	6
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England	6
The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Sys	6
Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment	6

Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments	6
Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer	6
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review	5
Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values	5
Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum	5
Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Advanced/Unresect	5
Incorporating Real Option Value in Valuing Innovation: A Way Forward	5
Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology	5
Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol	5
Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework	5
An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?	5
Reply to Comment on “Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective”	5
A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist	5
Cost-Effectiveness of a Digital Leakage Notification System (Heylo™) for People with Ileostomies or Colostomies in the United Kingdom	5
Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review	5
Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease	5
How Much Better is Faster? Value Adjustments for Health-Improvement Sequences	5
The Validity of the EuroQol Health and Wellbeing Short Version (EQ-HWB-S) Instrument in Parents of Children With and Without Health Conditions	5
Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease	5
Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens	5
Anchoring the Hemophilia Joint Health Score for Conventional Value Assessment in the Care of People Living with Severe Hemophilia A	5
A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses	5
Exploring the Use of Pictorial Approaches in the Development of Paediatric Patient-Reported Outcome Instruments: A Systematic Review	4
Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Gro	4
Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada	4
Cost-Effectiveness Analysis Methods Used in Evaluations of Treatment for Cystic Fibrosis: A Scoping Review	4
Mapping the Patient-Reported Outcomes Measurement Information System (PROMIS-29) to EQ-5D-5L	4
Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States	4
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial	4
Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses	4
Eladocagene Exuparvovec for the Treatment of Aromatic l-Amino Acid Decarboxylase Deficiency (AADCd): An Economic Evaluation from a US Perspective	4
Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid	4
Rapid Assessment of the Need for Evidence: Applying the Principles of Value of Information to Research Prioritisation	4
The RETRIEVE Checklist for Studies Reporting the Elicitation of Stated Preferences for Child Health-Related Quality of Life	4
A Comparison of PROPr and EQ-5D-5L Value Sets	4
Global Assessment of Health Utilities Associated with Pneumococcal Disease in Children—Targeted Literature Reviews	4
Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	4
An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L	4
Eliciting and Anchoring Health State Preferences Using Discrete Choice Experiments Among Adults, Adolescents, and Children	4
Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study)	4
Evaluating the Quantity and Quality of Health Economic Literature in Blinding Childhood Disorders: A Systematic Literature Review	4
Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab	4
Exploring the Economic Burden of Pulmonary Arterial Hypertension and Its Relation to Disease Severity and Treatment Escalation: A Systematic Literature Review	4
A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects	4
In a Child’s Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives	4
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management	4
Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?	3
The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia	3
Evaluating the Role and Policy Implications of Using External Evidence in Survival Extrapolations: A Case Study of Axicabtagene Ciloleucel Therapy for Second-Line DLBCL	3
The Influence of Perspective on the Valuation of the EQ-5D-Y-3L: A Comparison Using the OPUF Tool and a Discrete Choice Experiment	3
Correction: Exploring the Economic Burden of Pulmonary Arterial Hypertension and Its Relation to Disease Severity and Treatment Escalation: A Systematic Literature Review	3
Economic Analyses of Obsessive-Compulsive Disorder Interventions: A Systematic Review	3
Challenges in Modelling the Cost Effectiveness of Pharmacotherapies for Obesity	3
Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting	3
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy	3
Value-Based Healthcare in Practice: IDEATE, a Collaboration to Design and Test an Outcomes-Based Agreement for a Medicine in Wales	3
Accounting for Nonhealth and Future Costs in Cost-Effectiveness Analysis: Distributional Impacts of a US Cancer Prevention Strategy	3
Market and Non-Market Productivity Losses Associated with Invasive Meningococcal Disease in the USA	3
Estimating an EQ-5D-Y-3L Value Set for Brazil	3
PharmacoEconomics Supplement	3
How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents	3
Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers	3
Findings from a Roundtable Discussion with US Stakeholders on Valuation of the EQ-5D-Y-3L	3
Using Cure Modelling for Cost Effectiveness in the NICE Technology Appraisal of Polatuzumab Vedotin in Combination for Untreated Diffuse Large B Cell Lymphoma: An External Assessment Group Perspective	3
Integrating Environmental Impact in Health Technology Assessment: An Exploratory Study	3
Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer	3
Proxy Preferences and the Values of Children’s Health States	3
Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers	3
A Systematic Literature Review of Modelling Approaches to Evaluate the Cost Effectiveness of PET/CT for Therapy Response Monitoring in Oncology	3
Cost Effectiveness of Pharmacological and Non-pharmacological Treatments for Depression in Low- and Middle-Income Countries: A Systematic Literature Review	3
How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the Globe	3
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Recept	3
Artificial Intelligence as a New Research Ally? Performing AI-Assisted Systematic Literature Reviews in Health Economics	3
Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life to Inform Cost-Effectiveness Analysis: A Case Study of Fremanezumab in Japanese-Korean Migr	3
Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario	3
Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain	3
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review	3
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States	3
Making Decision Models Fit for Purpose: The Importance of Ensuring Stakeholder Involvement	3